Top

Archives of Gynecology and Obstetrics

Published in:

01-09-2015 | Maternal-Fetal Medicine

Uptake of non-invasive prenatal testing (NIPT) and impact on invasive procedures in a tertiary referral center

Authors: Gwendolin Manegold-Brauer, C. Berg, A. Flöck, A. Rüland, U. Gembruch, A. Geipel

Published in: Archives of Gynecology and Obstetrics | Issue 3/2015

Abstract

Purpose

The introduction of non-invasive prenatal testing (NIPT) by isolation of cell-free fetal DNA from maternal blood is a new diagnostic option in prenatal care. The aim of the study was to investigate the algorithm of prenatal testing before and after the introduction of NIPT in a tertiary referral center and to investigate the influence of NIPT on the frequency of invasive procedures.

Methods

Retrospective data analysis was conducted of all singleton pregnancies that presented for first trimester screening 17 months before and after the introduction of NIPT (n = 2271). Women were categorized into three risk groups: low risk for trisomy 21 (<1:1000), intermediate risk (1:101–1:1000) and high risk (≥1:100). The choice of diagnostic testing after FTS was analyzed.

Results

1093 (group 1) presented before and 1178 (group 2) after the introduction of NIPT. The rate of high-risk patients was equal in both groups (14.4 vs. 15.4 %). No differences were found with regard to invasive testing (11.6 vs. 11.3 %). NIPT was chosen by 3.7 % (44/1178) in group 2. Of those with NIPT, 72.7 % had a risk estimate of <1:100, but 90.9 % were ≥35 years old. The rate of NIPT among high-risk patients with a normal ultrasound examination was 25 %.

Conclusion

At present, NIPT is chosen mainly for reassurance by patients not considered to be at high risk. In the high-risk group, NIPT can be offered if the ultrasound examination is normal and the risk is high due to maternal age or serum screening alone. The rate of invasive testing was not reduced in this selected population.

Bianchi DW, Wilkins-Haug L (2014) Integration of noninvasive DNA testing for aneuploidy into prenatal care: what has happened since the rubber met the road? Clin Chem 60(1):78–87PubMedCrossRef

Chiu RWK, Lo YMD (2013) Clinical applications of maternal plasma fetal DNA analysis: translating the fruits of 15 years of research. Clin Chem Lab Med 51(1):197–204PubMed

Sehnert AJ, Rava RP, Bianchi DW (2013) A new era in noninvasive prenatal testing. N Engl J Med 369(22):2164–2165PubMedCrossRef

Bianchi DW, Oepkes D, Ghidini A (2014) Current controversies in prenatal diagnosis 1: should noninvasive DNA testing be the standard screening test for Down syndrome in all pregnant women? Prenat Diagn 34(1):6–11PubMedCrossRef

Kagan KO, Eiben B, Kozlowski P (2014) Kombiniertes Ersttrimesterscreening und zellfreie fetale DNA: “Next Generation Screening”. Ultraschall Med 35(3):229–236PubMedCrossRef

Syngelaki A, Pergament E, Homfray T, Akolekar R, Nicolaides KH (2014) Replacing the combined test by cell-free DNA testing in screening for trisomies 21, 18 and 13: impact on the diagnosis of other chromosomal abnormalities. Fetal Diagn Ther 35(3):174–184PubMedCrossRef

Nicolaides KH, Wright D, Poon LC, Syngelaki A, Gil MM (2013) First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell-free DNA testing. Ultrasound Obstet Gynecol 42(1):41–50PubMedCrossRef

Devers P, Cronister A, Ormond K, Facio F, Brasington C, Flodman P (2013) Noninvasive prenatal testing/noninvasive prenatal diagnosis: the position of the national society of genetic counselors. J Genet Couns. 22(3):291–295PubMedCrossRef

Benn P, Borell A, Chiu R, Cuckle H, Dugoff L, Faas B et al (2013) Position statement from the Aneuploidy Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis. Prenat Diagn 33(7):622–629PubMedCrossRef

10.

Committee Opinion No. 545 (2012) Noninvasive prenatal testing for fetal aneuploidy. Obstet Gynecol 120(6):1532–1534CrossRef

11.

Kagan KO, Etchegaray A, Zhou Y, Wright D, Nicolaides KH (2009) Prospective validation of first-trimester combined screening for trisomy 21. Ultrasound Obstet Gynecol 34(1):14–18PubMedCrossRef

12.

Ekelund CK, Jørgensen FS, Petersen OB, Sundberg K, Tabor A (2008) Impact of a new national screening policy for Down’s syndrome in Denmark: population based cohort study. BMJ 337:a2547PubMedCentralPubMedCrossRef

13.

Wapner R, Thom E, Simpson JL, Pergament E, Silver R, Filkins K et al (2003) First-trimester screening for trisomies 21 and 18. N Engl J Med 349(15):1405–1413PubMedCrossRef

14.

Hagen A, Entezami M, Gasiorek-Wiens A, Albig M, Becker R, Knoll U et al (2011) The impact of first trimester screening and early fetal anomaly scan on invasive testing rates in women with advanced maternal age. Ultraschall Med 32(3):302–306PubMedCrossRef

15.

Haddow JE, Palomaki GE, Knight GJ, Cunningham GC, Lustig LS, Boyd PA (1994) Reducing the need for amniocentesis in women 35 years of age or older with serum markers for screening. N Engl J Med 330(16):1114–1118PubMedCrossRef

16.

Wray AM, Ghidini A, Alvis C, Hodor J, Landy HJ, Poggi SH (2005) The impact of first-trimester screening on AMA patients’ uptake of invasive testing. Prenat Diagn 25(5):350–353PubMedCrossRef

17.

Geipel A, Daiss T, Katalinic A, Germer U, Kohl T, Krapp M et al (2007) Changing attitudes towards non-invasive aneuploidy screening at advanced maternal age in a German tertiary care center. Ultraschall Med 28(1):67–70PubMedCrossRef

18.

Lüthgens K, Merz E, Hackelöer BJ, Thode C, Eiben B, Kagan KO (2013) Comparison of three first trimester screening algorithms for trisomy 21 with and without adjustment for maternal characteristics. Ultraschall Med 34(2):151–156PubMed

19.

Nicolaides KH (2011) Screening for fetal aneuploidies at 11 to 13 weeks. Prenat Diagn 31(1):7–15PubMedCrossRef

20.

Kagan KO, Wright D, Spencer K, Molina FS, Nicolaides KH (2008) First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics. Ultrasound Obstet Gynecol 31(5):493–502PubMedCrossRef

21.

Chiu R, Akolekar R, Zheng YWL, Leung T, Sun H, Chan K et al (2011) Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study. BMJ 432:c7401CrossRef

22.

Ehrich M, Deciu C, Zwiefelhofer T, Tynan JA, Cagasan L, Tim R et al (2011) Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting. Am J Obstet Gynecol 204(205):e1–e11

23.

Sparks AB, Struble CA, Wang ET, Song K, Oliphant A (2012) Non-invasive prenatal detection and selective analysis of cell-free DNA obtained from maternal blood: evaluation for trisomy 21 and trisomy 18. Am J Obstet Gynecol 206(322):e1–e5PubMed

24.

Palomaki GE, Kloza EM, Lambert-Messerlian GM, Haddow JE, Neveux LM, Ehrich M et al (2011) DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet Med Off J Am Coll Med Genet. 13:913–920

25.

Chen E, Chiu RWK, Sun H, Akolekar R, Chan K, Leung T et al (2011) Noninvasive prenatal diagnosis of fetal trisomy 18 and trisomy 13 by maternal plasma DNA sequencing. PLoS ONE 6(7):e21791PubMedCentralPubMedCrossRef

26.

Bianchi DW, Platt LD, Goldberg JD, Abuhamad AZ, Sehnert AJ, Rava RP (2012) Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet Gynecol 119:1–13CrossRef

27.

Norton ME, Brar H, Weiss J, Karimi A, Laurent LC, Caughey AB et al (2012) Non-invasive chromosomal evaluation (NICE) study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18. Am J Obstet Gynecol 207:1–8CrossRef

28.

Guex N, Iseli C, Syngelaki A, Deluen C, Pescia G, Nicolaides KH et al (2013) A robust second-generation genome-wide test for fetal aneuploidy based on shotgun sequencing cell-free DNA in maternal blood. Prenat Diagn 33(7):707–710PubMedCrossRef

29.

Gil MM, Akolekar R, Quezada MS, Bregant B, Nicolaides KH (2014) Analysis of cell-free DNA in maternal blood in screening for aneuploidies: meta-analysis. Fetal Diagn Ther 35(3):156–173PubMedCrossRef

30.

Wellesley D, Dolk H, Boyd PA, Greenlees R, Haeusler M, Nelen V et al (2012) Rare chromosome abnormalities, prevalence and prenatal diagnosis rates from population-based congenital anomaly registers in Europe. Eur J Hum Genet 20(5):521–526PubMedCentralPubMedCrossRef

31.

Chetty S, Garabedian MJ, Norton ME (2013) Uptake of noninvasive prenatal testing (NIPT) in women following positive aneuploidy screening. Prenat Diagn 33(6):542–546PubMedCrossRef

32.

Friel LA, Czerwinski JL, Singletary CN (2014) The impact of noninvasive prenatal testing on the practice of maternal-fetal medicine. Am J Perinatol 31(9):759–764PubMed

33.

Kagan KO, Avgidou K, Molina FS, Gajewska K, Nicolaides KH (2006) Relation between increased fetal nuchal translucency thickness and chromosomal defects. Obstet Gynecol 107(1):6–10PubMedCrossRef

34.

Manegold-Brauer G, Kang Bellin A, Hahn S, De Geyter C, Buechel J, Hoesli I et al (2014) A new era in prenatal care: non-invasive prenatal testing (NIPT) in Switzerland. Swiss Med Wkly. 144:w13915PubMed

35.

Platt LD, Janicki MB, Prosen T, Goldberg JD, Adashek J, Figueroa R et al (2014) Impact of noninvasive prenatal testing in regionally dispersed medical centers in the United States. Am J Obstet Gynecol 211(4):368.e1–368.e7CrossRef

36.

Gil MM, Quezada MS, Bregant B, Ferraro M, Nicolaides KH (2013) Implementation of maternal blood cell-free DNA testing in early screening for aneuploidies. Ultrasound Obstet Gynecol 42(1):34–40PubMedCrossRef

Title: Uptake of non-invasive prenatal testing (NIPT) and impact on invasive procedures in a tertiary referral center
Authors: Gwendolin Manegold-Brauer
C. Berg
A. Flöck
A. Rüland
U. Gembruch
A. Geipel
Publication date: 01-09-2015
Publisher: Springer Berlin Heidelberg
Published in: Archives of Gynecology and Obstetrics / Issue 3/2015
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-015-3674-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Uptake of non-invasive prenatal testing (NIPT) and impact on invasive procedures in a tertiary referral center

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2015

Introduction of a nomogram for predicting adverse pregnancy outcomes based on maternal serum markers in the quad screen test

Antenatal imaging of anomalies of the corpus callosum: a decade of experience

Risk factors predicting an emergency cesarean delivery for the second twin after vaginal delivery of the first twin

Reply to: Continuous or cyclic contraceptives for endometriosis: a question still without an answer

Investigating the effects of treatment based on single high blood glucose in gestational diabetes screening on maternal and neonatal complications

Effects of serum from patients with early-onset pre-eclampsia, HELLP syndrome, and antiphospholipid syndrome on fatty acid oxidation in trophoblast cells